

# **POSTER PRESENTATION**



# NAMPT/Visfatin expression by inflammatory monocytes mediates arthritis pathogenesis by promoting IL-17–producing T cells

Jessy Présumey<sup>1,2</sup>, Gabriel Courties<sup>1,2</sup>, Pascale Louis-Plence<sup>1,2</sup>, Virginie Escriou<sup>3,4,5,6</sup>, Daniel Scherman<sup>3,4,5,6</sup>, Yves-Marie Pers<sup>1,2,7</sup>, Hans Yssel<sup>1,2</sup>, Jérôme Pène<sup>1,2</sup>, Diego Kyburz<sup>8</sup>, Steffen Gay<sup>8</sup>, Christian Jorgensen<sup>1,2,7</sup>, Florence Apparailly<sup>1,2,7\*</sup>

*From* 7th European Workshop on Immune-Mediated Inflammatory Diseases Noordwijk aan Zee, the Netherlands. 28-30 November 2012

# Background

Nicotinamide phosphoribosyltransferase (NAMPT)/PBEF/ Visfatin exerts multiple functions and has been implicated in the pathogenesis of rheumatoid arthritis. The expression of NAMPT is increased during inflammation and is identified as a novel mediator of innate immunity. To gain insight into its role in arthritis and given that NAMPT induces IL-6 expression that is critical for Th17 lymphocytes, we hypothesized that NAMPT-stimulated production of IL-6 by monocytes might in turn promote Th17 cells.

## Materials and methods

siRNA uptake and NAMPT expression were determined in Ly6C<sup>high</sup> and Ly6C<sup>low</sup> monocyte subsets following intravenous injection of siRNA against NAMPT (siNAMPT) or non-targeting siRNA (siCT) formulated with the DMA-PAP cationic liposome into mice. Mice with established collagen-induced arthritis (CIA) were treated weekly after disease onset with siNAMPT or siCT and clinical features were assessed. T helper cell frequencies, cytokine production and percentage of IL-6-producing Ly6C<sup>high</sup> monocytes were analyzed. Using a coculture system consisting of purified CD14<sup>+</sup> monocytes and autologous CD4<sup>+</sup> T cells, NAMPT and cytokine production, as well as the percentage of IL-17-producing CD4<sup>+</sup> T cells were determined following transfection of CD14<sup>+</sup> monocytes with siCT or siNAMPT.

<sup>1</sup>INSERM, U844, Montpellier, France

Full list of author information is available at the end of the article

### Results

Upon intravenous injection, siRNA was preferentially engulfed by Ly6C<sup>high</sup> monocytes and siRNA-mediated silencing of NAMPT expression in Ly6C<sup>high</sup> monocytes reduced IL-6 production by these cells, mitigated Th17 cell expansion, and inhibited inflammatory features and CIA progression. Moreover, NAMPT-RNAi-silenced CD14<sup>+</sup> monocytes were found to reduce the percentage of IL-17-producing CD4<sup>+</sup> T cells.

#### Conclusions

Taken together, our results show that the expression of NAMPT in Ly6C<sup>high</sup> monocytes promotes Th17 cells. Our findings provide new mechanistic insight into the action of NAMPT in arthritis and demonstrate the utility of targeting disease-causing genes in Ly6C<sup>high</sup> monocytes for therapeutic intervention in arthritis.

#### Author details

<sup>1</sup>INSERM, U844, Montpellier, France. <sup>2</sup>University of Medicine, Montpellier, France. <sup>3</sup>INSERM, U1022, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France. <sup>4</sup>CNRS, UMR8151, Paris, France. <sup>5</sup>University of Pharmacy Paris Descartes, Paris, France. <sup>6</sup>Ecole Nationale Supérieure de Chimie de Paris, Paris, France. <sup>7</sup>University Hospital of Montpellier, Clinical Dept. for osteoarticular diseases, Montpellier, France. <sup>8</sup>Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology, Zurich, Switzerland.

Published: 28 November 2012



doi:10.1186/1479-5876-10-S3-P48 Cite this article as: Présumey et al.: NAMPT/Visfatin expression by inflammatory monocytes mediates arthritis pathogenesis by promoting IL-17-producing T cells. Journal of Translational Medicine 2012 10(Suppl 3): P48.

© 2012 Présumey et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.